Guangxi Chunzhengtang Pharmaceutical Co., Ltd.

Primary Objective To observe the pharmacokinetic process of ilaprazole enteric-coated tablets after a single oral dose in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and evaluate bioequivalence using ilaprazole enteric-coated tablets (Yilian®) manufactured by Livzon Pharmaceutical Factory, a subsidiary of Livzon Pharmaceutical Group, as the reference formulation. Secondary Objective To evaluate the safety of a single oral dose of ilaprazole enteric-coated tablets (5 mg strength) and the reference formulation (5 mg strength) in healthy Chinese subjects.

Primary Objective: To investigate the in vivo time course of olopatadine in healthy subjects following single oral administration of olopatadine hydrochloride granules (test formulation, strength: 2.5 mg (0.5 g/bag, 0.5%)) produced by Chengdu Tiantaishan Pharmaceutical Co., Ltd. (owned by Jiuhua Huayuan Pharmaceutical (Guilin) Co., Ltd.) and olopatadine hydrochloride granules (reference formulation, trade name: Allelock®, strength: 2.5 mg (0.5 g/bag, 0.5%)) produced by Kyowa Kirin Co., Ltd. (Kyowa Kirin Co., Ltd.) in both fasting and fed states using a randomized, open-label, two-period, two-sequence, double-crossover design. The aim was to estimate relevant pharmacokinetic parameters and relative bioavailability, and to evaluate their bioequivalence in both fasting and fed states, thereby providing a basis for the production registration application of the test formulation. Secondary Objective: To evaluate the safety of the test formulation and reference formulation (trade name: Allelock®) of olopatadine hydrochloride granules in healthy subjects.

Main purpose: With healthy subjects as the test subjects, a randomized, open, two-period, two-sequence, double-crossover design was used to investigate the in vivo time course of trazodone after a single oral administration of trazodone hydrochloride sustained-release tablets (test preparation, specification: 150 mg) produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd. (held by Jiuhua Huayuan Pharmaceutical (Guilin) Co., Ltd.) and trazodone hydrochloride sustained-release tablets (reference preparation, trade name: Trittico®\Trittico®, specification: 150 mg) produced by Az.Chim.Riun.Angelini Francesco Acraf S.P.A. on fasting and after meals, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in fasting and after meals, and provide a basis for the production registration application of the test preparation. Secondary purpose: To evaluate the safety of the test preparation and reference preparation (trade name: Trittico®\Trittico®) of trazodone hydrochloride sustained-release tablets in healthy subjects.